NCT07006012
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +6 more
- Locations
-
- Fudan University Shanghai Cancer Center Shanghai, Shanghai Municipality, China
Clinical trial condition
Lymphoma Patients With Complete Response (CR) or Partial Response (PR) After Standard Treatment Had a Positive Minimal Residual Lesion (MRD)
Explore clinical trials studying Lymphoma Patients With Complete Response (CR) or Partial Response (PR) After Standard Treatment Had a Positive Minimal Residual Lesion (MRD). Study availability and eligibility vary by location and protocol.
1 public trial
1 recruiting study